Trial Profile
An Open Randomized Therapeutic Trial Using ANAKINRA, TOCILIZUMAB Alone or in Association With RUXOLITINIB in Severe Stage 2b and 3 of COVID19-associated Disease
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 09 Feb 2023
Price :
$35
*
At a glance
- Drugs Anakinra (Primary) ; Anakinra (Primary) ; Ruxolitinib (Primary) ; Ruxolitinib (Primary) ; Tocilizumab (Primary) ; Epinephrine
- Indications Adult respiratory distress syndrome; COVID 2019 infections; Pneumonia
- Focus Therapeutic Use
- Acronyms INFLAMMACOV
- 05 Jul 2021 This trial has been discontinued in France (End Date: 09 Jul 2021), according to European Clinical Trials Database record.
- 02 Jun 2020 New trial record